Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have been given a consensus recommendation of “Buy” by the nine analysts that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $339.17.

BIO has been the subject of several research reports. Barclays raised Bio-Rad Laboratories from an “equal weight” rating to an “overweight” rating and set a $315.00 target price for the company in a research note on Thursday, January 3rd. Goldman Sachs Group initiated coverage on Bio-Rad Laboratories in a research note on Wednesday, October 17th. They set a “buy” rating and a $350.00 target price for the company. Finally, Zacks Investment Research cut Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a research note on Monday, November 12th.

In related news, EVP Michael Crowley sold 392 shares of the stock in a transaction on Friday, December 14th. The stock was sold at an average price of $248.03, for a total value of $97,227.76. Following the completion of the transaction, the executive vice president now owns 3,425 shares in the company, valued at approximately $849,502.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Annette Tumolo sold 2,376 shares of the stock in a transaction on Tuesday, December 11th. The shares were sold at an average price of $254.51, for a total value of $604,715.76. Following the completion of the transaction, the executive vice president now owns 1,504 shares of the company’s stock, valued at approximately $382,783.04. The disclosure for this sale can be found here. Insiders sold a total of 5,027 shares of company stock valued at $1,267,916 in the last quarter. 27.99% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in BIO. Levin Capital Strategies L.P. boosted its position in shares of Bio-Rad Laboratories by 7,126.2% in the 4th quarter. Levin Capital Strategies L.P. now owns 569,205 shares of the medical research company’s stock valued at $132,181,000 after purchasing an additional 561,328 shares during the period. Federated Investors Inc. PA boosted its position in shares of Bio-Rad Laboratories by 2,080.5% in the 3rd quarter. Federated Investors Inc. PA now owns 237,562 shares of the medical research company’s stock valued at $74,354,000 after purchasing an additional 226,667 shares during the period. Select Equity Group L.P. boosted its position in shares of Bio-Rad Laboratories by 321.8% in the 3rd quarter. Select Equity Group L.P. now owns 186,923 shares of the medical research company’s stock valued at $58,505,000 after purchasing an additional 142,604 shares during the period. Bodenholm Capital AB acquired a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at $32,540,000. Finally, AQR Capital Management LLC boosted its position in shares of Bio-Rad Laboratories by 163.4% in the 3rd quarter. AQR Capital Management LLC now owns 159,008 shares of the medical research company’s stock valued at $49,768,000 after purchasing an additional 98,634 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Shares of BIO opened at $248.85 on Friday. The firm has a market cap of $7.46 billion, a PE ratio of 60.70, a price-to-earnings-growth ratio of 2.45 and a beta of 1.21. The company has a current ratio of 4.49, a quick ratio of 3.16 and a debt-to-equity ratio of 0.09. Bio-Rad Laboratories has a one year low of $220.05 and a one year high of $345.15.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Story: Depreciation

Analyst Recommendations for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.